小剂量硼替佐米联合化疗治疗4例多发性骨髓瘤的疗效

Efficacy of low-dose bortezomib combined with chemotherapy in 4 patients with multiple myeloma

目的观察小剂量硼替佐米联合化疗治疗复发难治或初发多发性骨髓瘤（MM）的疗效和不良反应。方法4例MM患者接受硼替佐米＋环磷酰胺＋地塞米松＋沙利度胺治疗，每3周为一疗程。所有患者接受2～4疗程的治疗。采用EBMT疗效标准评价疗效，按国立癌症研究所的常规毒性判定标准评价不良反应。结果4例MM患者中1例接近完全缓解，3例部分缓解。不良反应有白细胞减少、血小板减少、肺部感染等。结论小剂量硼替佐米联合化疗可作为复发难治或初发MM的治疗选择。

AIM To investigate the efficacy and toxicity of bortezomib in combination with chemotherapy for the treatment of patients with relapsed or refractory and newly diagnosed multiple myeloma （MM）. METHODS Four MM patients received the treatment of low-dose bortezomib（ 1.0 mg·m^-2 ） in combination with cyclophosphamide, dexamethasone and thalidomide in a 21-day cycle. All patients underwent 2 - 4 cycles of the treatment. Response to bortezomibcontaining regimen was evaluated according to the criteria of the European Cooperative Group for Bone Marrow Transplantation（EBMT）. Adverse drug reactions were graded according to the National Cancer Institute common toxicity criteria. RESULTS In 4 MM patients, one patient achieved near complete remission while partial remission was observed in the other 3 patients. Main adverse drug reactions were found including leucocytopenia, thrombocytopenia and pneumonia and so on. CONCLUSION The combination of low-dose bortezomib and chemotherapy can be safely and effectively used for the MM patients.